Loading...
XNASBIVI
Market cap41mUSD
Jan 06, Last price  
2.23USD
1D
2.29%
1Q
87.39%
Jan 2017
-93.95%
IPO
-92.24%
Name

BioVie Inc

Chart & Performance

D1W1MN
XNAS:BIVI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
77.85%
Rev. gr., 5y
%
Revenues
0k
Net income
-32m
L-36.09%
-70,040-321,896-233,008-431,923-1,330,673-2,434,117-2,492,946-33,775,826-183,847,000-26,084,468-50,255,814-32,120,533
CFO
-28m
L-30.58%
-10,040-172,832-65,383-163,631-623,615-621,341-2,501,577-1,628,228-10,453,047-18,990,850-40,252,881-27,945,024
Earnings
Feb 11, 2025

Profile

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
URL
https://www.bioviepharma.com/
IPO date
Jan 14, 2014
Employees
18
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
Cost of revenue
23,330
33,566
17,496
Unusual Expense (Income)
NOPBT
(23,330)
(33,566)
(17,496)
NOPBT Margin
Operating Taxes
4,300
(3,287)
Tax Rate
NOPAT
(23,330)
(37,866)
(14,208)
Net income
(32,121)
-36.09%
(50,256)
92.67%
(26,084)
-85.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
27,803
55,371
18,511
BB yield
-1,536.35%
-395.50%
-517.64%
Debt
Debt current
5,762
9,150
39
Long-term debt
760
5,357
12,352
Deferred revenue
Other long-term liabilities
48
Net debt
(17,322)
(19,431)
(6,250)
Cash flow
Cash from operating activities
(27,945)
(40,253)
(18,991)
CAPEX
Cash from investing activities
14,525
(14,301)
Cash from financing activities
17,803
55,373
33,121
FCF
(23,656)
(37,829)
(14,327)
Balance
Cash
23,844
33,939
18,642
Long term investments
Excess cash
23,844
33,939
18,642
Stockholders' equity
(334,226)
(301,045)
(250,967)
Invested Capital
355,844
330,809
266,952
ROIC
ROCE
EV
Common stock shares outstanding
4,519
3,248
2,466
Price
0.40
-90.71%
4.31
197.24%
1.45
-91.45%
Market cap
1,810
-87.07%
14,000
291.50%
3,576
-82.99%
EV
(15,512)
(5,431)
(2,674)
EBITDA
(23,100)
(33,337)
(17,266)
EV/EBITDA
0.67
0.16
0.15
Interest
2,894
4,300
2,163
Interest/NOPBT